# Antiva Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/antiva-biosciences

- Industry: Biotechnology
- Headquarters: Brisbane, US
- Website: www.antivabio.com
- Total disclosed funding: $84M
- Latest round: Series E (Apr 24, 2023)
- Investors on record: 17

## About

Antiva Biosciences, Inc., based in the US, specializes in developing innovative topical antiviral treatments for women, specifically targeting pre-cancerous cervical lesions associated with human papillomavirus (HPV).Antiva Biosciences, Inc. is focused on creating advanced treatments for cervical health issues caused by HPV. Founded in Brisbane, US in 2012, the company has successfully raised funding for its projects, with the most recent funding round being the SERIES E, which raised USD 26.56 mn on April 24, 2023. The funding was led by MPM BioImpact with participation from other significant investors like Adjuvant Capital and Canaan Partners. The company was founded by Karl Hostetler and has engaged in nine deals to date.Antiva Biosciences is dedicated to developing a topical antiviral treatment aimed at combating pre-cancerous cervical lesions caused by human papillomavirus (HPV). Their core product empowers women by providing a non-invasive, home-based management option for HPV infections, addressing a critical need for safer and less invasive treatment alternatives. Their target market includes women in North America and parts of Europe who face limited treatment options for HPV-related health issues.Antiva Biosciences employs a direct-to-consumer business model for its antiviral treatments, facilitating access for patients. Their revenue generation structure may involve partnerships with healthcare providers and retail pharmacies to enhance distribution. The company's pricing strategy aims to offer affordable access to treatments through a once-off purchase model or subscription services, ensuring continuity in supply for women managing HPV infections and associated lesions.In April 2023, Antiva Biosciences, Inc. secured USD 26.56 mn in SERIES E funding to further develop its lead candidate, ABI-2280, advancing into key efficacy studies following the completion of its Phase 1 trial. The company plans to expand its market reach into new geographic regions, focusing on areas with significant demand for HPV-related health solutions. The recent funding will be instrumental in supporting these initiatives, helping to establish a robust market presence.

## Funding rounds

- Series E, Apr 24, 2023, $27M — Sofinnova Investments, Canaan Partners, HBM Partners, MPM BioImpact, GV, Adjuvant Capital, Lumira Ventures
- Series D, Oct 25, 2021, $16M — Sofinnova Investments, Canaan Partners, HBM Partners, Alexandria Venture Investments, OUP (Osage University Partners), GV, Brace Pharma Capital, Gaingels, Sirona Capital, Adjuvant Capital, Avestria Ventures, Mana Ventures, Dong-A ST Co., Ltd., Lumira Ventures
- Series C, Jul 6, 2018, $15M — Sofinnova Investments, Canaan Partners, Alexandria Venture Investments, OUP (Osage University Partners), Hillhouse Investment, Brace Pharma Capital, Timefolio Capital, Sirona Capital, Lumira Ventures
- Series C, Feb 15, 2017, $11M — Sofinnova Investments, Canaan Partners, Alexandria Venture Investments, OUP (Osage University Partners), Brace Pharma Capital, Timefolio Capital
- Series B, Aug 6, 2015, $16M — Sofinnova Investments, Canaan Partners

## Investors

- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B, Series C, Series D, Series E
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series B, Series C, Series D, Series E
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series C, Series D
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series C, Series D
- Brace Pharma Capital (https://capitalatlas.ai/funds/brace-pharma-capital) — Series C, Series D
- Timefolio Capital — Series C
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series C
- Sirona Capital (https://capitalatlas.ai/funds/sirona-capital) — Series C, Series D
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series C, Series D, Series E
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series D, Series E
- GV (https://capitalatlas.ai/funds/gv) — Series D, Series E
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series D
- Adjuvant Capital (https://capitalatlas.ai/funds/adjuvant-capital) — Series D, Series E
- Avestria Ventures (https://capitalatlas.ai/funds/avestria-ventures) — Series D
- Mana Ventures (https://capitalatlas.ai/funds/mana-ventures) — Series D
- Dong-A ST Co., Ltd. — Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series E